drugset
drugset / Trial / NCT02752516

A Phase I Additional Study of Anlotinib on Tolerance and Pharmacokinetics

NCT02752516 ↗

Phase 1 Unknown 16 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

A Phase I Additional Study of Anlotinib on Tolerance and Pharmacokinetics.To further study the pharmacokinetic characteristics of Anlotinib in the human body, recommend a reasonable regimen for subsequent research.

Timeline

Start
2016-04-27
Primary completion
2017-12
Completion
2017-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Catequentinib Small molecule — Oral

Indications

cancer